top of page

Get Molecular Testing - Canada
(non-ON/non-QC)

As of July 1st, 2024, patients living with cholangiocarcinoma that reside outside of Ontario and Quebec will be able to access molecular testing from OncoHelix Labs, in partnership with the C3. OncoHelix-C3 molecular testing will use the 170 gene CGP "OncoHelix-2" panel, which can detect FGFR2 fusions and other DNA/RNA biomarkers (see below for full list).

 

Patients and treating physicians will receive a complete clinical report of Tier I (variants of strong clinical significance) and Tier II (variants of potential clinical significance) alterations in DNA and RNA biomarkers.

Important information:

  • Patients must be a "C3 Member"

  • ​The OncoHelix-C3​ test requisition form should be submitted to c3@ohri.ca

    • Sample and Pathology details are on Page 2

  • Biopsy brushings are accepted and will undergo OncoHelix's standard Quality Control tests to ensure suitability for molecular testing.

    • If you are submitting brushings, please check "Other" and specify. 

Links for OncoHelix x C3:

NOTICE FOR ALBERTA ONLY: 

For molecular testing requests from Alberta, please contact the c3@ohri.ca first before submitting a test requisition form. 
 

Contact and Assistance Information:

image.png

*OncoHelix Labs is accredited by the College of Physicians and Surgeons of Alberta (CPSA) and performs all testing to CPSA Standards

ONCOHELIX-C3 GENE LIST updated.png
  • Instagram
  • Facebook
  • Twitter
image.png
leaf-cihr-colour-en_edited.png

The Canadian Cholangiocarcinoma Collaborative (C3) is supported by a Canadian Cancer Society Breakthrough Team Grant in partnership with the Canadian Institutes of Health Research. The granting funds for C3 are managed by The Ottawa Hospital Research Institute, which serves as the lead institute for all collaborative operations.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page